Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ovarian reserve markers in women using various hormonal contraceptives

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Concerns on future fertility among users and past-users of combined oral contraceptives: a questionnaire survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hepatotoxicity induced by a second-generation combined oral contraceptive: case report and review of the literature

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Identification of a unique epigenetic profile in women with diminished ovarian reserve

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A distinctive epigenetic ageing profile in human granulosa cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms

    Research output: Contribution to journalReviewResearchpeer-review

  • Santiago Palacios
  • Pedro-Antonio Regidor
  • Enrico Colli
  • Sven Olaf Skouby
  • Dan Apter
  • Thomas Roemer
  • Christian Egarter
  • Rossella E Nappi
  • Aleš Skřivánek
  • Artur J Jakimiuk
  • Steven Weyers
  • Nándor Ács
  • David Elia
  • Kristina Gemzell Danielsson
  • Johannes Bitzer
View graph of relations

Purpose: The contraceptive pill is an effective and safe method of preventing pregnancy. The progestins used for contraception either are components of a combined hormonal contraceptive (tablets, patches or vaginal rings) or are used alone in progestin-only formulations. Progestin-only contraceptives are available as daily oral preparations, subcutaneous or intramuscular injectables (every 1-3 months), subdermal implants (every 3-5 years) and intrauterine systems (every 3-5 years). Long-acting progestins are highly effective in typical use and have a very low risk profile and few contraindications.Material and Methods: A new progestin-only, oestrogen-free contraceptive, drospirenone, in a dosage of 4 mg/day in a 24/4 regimen, has received regulatory approval in the USA and the EU. The molecule has antigonadotropic, antimineralocorticoid, antiestrogenic and antiandrogenic properties.Results: The regimen was chosen to improve the bleeding profile; maintain plasma oestradiol levels at those of the early follicular phase, to avoid hypoestrogenism; and preserve efficacy even with a missed pill, as drospirenone has a half-life of 30-34 h.Conclusions: Clinical studies have shown good efficacy, very low cardiovascular side effects and a favourable bleeding pattern, as well as maintenance of ovulation inhibition after scheduled 24 h delays in pill intake.

Original languageEnglish
JournalThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
Volume25
Issue number3
Pages (from-to)221-227
Number of pages7
ISSN1362-5187
DOIs
Publication statusPublished - Jun 2020

ID: 62405885